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Background: Although the association between lead and cardiovascular disease is well established, potential
mechanisms are still poorly understood. Calcium metabolism plays a role in lead toxicity and thus, vitamin D
receptor (VDR) polymorphisms have been suggested to modulate the association between lead and health
outcomes. We investigated effect modification by VDR genetic polymorphisms in the association between
cumulative lead exposure and pulse pressure, a marker of arterial stiffness.
Methods: We examined 727 participants (3,100 observations from follow-ups from 1991 to 2011) from the Normative
Aging Study (NAS), a longitudinal study of aging. Tibia and patella bone lead levels were measured using K-x-ray
fluorescence. Four single nucleotide polymorphisms (SNPs) in the VDR gene, Bsm1, Taq1, Apa1, and Fok1, were
genotyped. Linear mixed effects models with random intercepts were implemented to take into account repeated
measurements.
Results: Adjusting for potential confounders, pulse pressure was 2.5 mmHg (95% CI: 0.4-4.7) and 1.9 mmHg (95% CI:
0.1-3.8) greater per interquartile range (IQR) increase in tibia lead (15 μg/g) and patella lead (20 μg/g), respectively, in
those with at least one minor frequency allele in Bsm1 compared with those with major frequency allele homozygotes.
The observed interaction effect between bone lead and the Bsm1 genotype persists over time during the follow-up.
Similar results were observed in effect modification by Taq1.
Conclusions: This study suggests that subjects with the minor frequency alleles of VDR Bsm1 or Taq1 may be more
susceptible to cumulative lead exposure-related elevated pulse pressure.
Keywords: Lead, Vitamin D receptor, Gene by environmental interaction, A longitudinal studyBackground
Lead (Pb) is known to increase the risk of cardiovascular
diseases (CVD). A recent expert review by the National
Toxicology Program (NTP) concluded that there is suffi-
cient evidence that long-term cumulative exposure, even
at low level exposure, which can be assessed by bone lead
levels used in our study, is associated with elevated blood
pressure [1]. Several studies have identified a positive* Correspondence: sungkyun@umich.edu
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unless otherwise stated.association between lead exposure and high blood pres-
sure, which is a major risk factor for CVD. Martin et al.
[2] found an association between blood lead levels and in-
creases in blood pressure, as well as an association be-
tween tibia bone lead levels and hypertension in the
Baltimore Memory Study. Cheng et al. [3] reported an in-
creased risk of incident hypertension with higher levels of
lead in tibia and patella bones in the Normative Aging
Study (NAS). Another study, which used the NAS data,
found an association between high lead levels in bone and
blood and hypertension among subjects with low dietary
calcium intake [4]. Blood lead levels have also beenhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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hypertension [5]. The association between lead expos-
ure and the risk of hypertension in pregnant women
was also demonstrated even in those with blood lead
levels less than 2 μg/dL [6]. Lead exposure may also in-
duce endothelial injury and atherosclerosis [7-9]. The
study by Perlstein et al. [10] suggests that lead accumula-
tion may contribute to the increase in pulse pressure, a
measure of arterial stiffness, and with clinical cardiovas-
cular events. Zhang et al. [11] also reported a deleterious
impact of cumulative lead on pulse pressure with effect
modification by hemochromatosis genetic polymorphism
in the NAS.
Vitamin D receptor (VDR) is involved in lead absorp-
tion and accumulation [12]. Vitamin D plays an import-
ant role in calcium metabolism, which is shared by lead
[13]. Calcitriol, an active hormonal form of vitamin D,
stimulates increased calcium absorption from the gut
during calcium deficiency. Calcitriol also stimulates the
expression of genes engaged in absorption of calcium in
the intestine. The effects of vitamin D and calcitriol are
mediated by their interaction with the VDR. The com-
plex of calcitriol and VDR acts as a transcription factor
regulating the gene expression of calcium-binding recep-
tors. Because lead is a divalent cation, lead competes
with calcium to bind to calcium-binding receptors [14].
When calcium levels are low, the calcium-binding pro-
tein may bind lead instead of calcium, resulting in ele-
vated absorption of lead [15]. The VDR genetic variants
have been identified as potential genetic factors that can
influence the absorption, retention and accumulation of
lead in the human body [12]. Schwartz et al. [16] exam-
ined former organolead manufacturing workers and
found that Bsm1 variant on the VDR gene modifies the
association between age and tibia bone lead levels. In
this study, the cumulative level of lead in bone and the
rate of reabsorption and excretion of lead over time were
higher for those with the VDR Bsm1 variant. This study
suggests that the VDR genetic variant may play a role in
susceptibility to lead accumulation.
Vitamin D and VDR are involved in arterial stiffness
and arterial aging [17,18]. Vitamin D has been demon-
strated to regulate endothelial nitric oxide synthase and
arterial stiffness in a mouse study [19]. Lower serum
vitamin D3 levels are known to be associated with
hypertension [20]. VDR is also involved in the renin-
angiotensin system, cell proliferation and differentiation,
anti-inflammation, and anti-fibrosis [21]. The effect of
VDR on immune response and inflammation has been re-
lated to atherosclerosis [22].
There have been studies examining effect modification
of lead by VDR in relation to several diseases [23,24].
However, effect modification by VDR genotype in the as-
sociation between lead and subclinical CVD measures,including arterial stiffness in longitudinal settings, has
not yet been examined. In this study, we investigate ef-
fect modification by the VDR gene in the association be-
tween cumulative lead exposure measured by bone lead
levels and pulse pressure, a marker of arterial stiffness.
Methods
Study population
The NAS is a longitudinal study of the aging process
established by the Veterans Administration in 1963 at
the VA Outpatient Clinic in Boston, Massachusetts. The
participants were 2,280 mostly White men aged 21 to
80 years with no past or present known chronic condi-
tions (heart disease, cancer, recurrent asthma, sinusitis,
bronchitis, diabetes, gout, peptic ulcer, or hypertension)
[25]. The NAS followed up on the participants every 3
to 5 years.
The NAS participants were invited to obtain bone lead
measurements between 1991 and 1999 at the Ambula-
tory Clinical Research Center of the Brigham and
Women’s Hospital in Boston, Massachusetts (N = 866).
Of the participants with bone lead measurements, nine
participants were excluded due to unreliable bone lead
measurements (detailed description in the lead exposure
section). Of 857 participants, 727 participants were suc-
cessfully genotyped for at least one single nucleotide poly-
morphisms (SNP) on the VDR gene including Bsm1
(rs1544410), Taq1 (rs731236), Apa1 (rs7975232), and
Fok1 (rs10735810). The present analysis includes pulse
pressure measured at the time of bone lead measure-
ment (baseline, 1991–1999) and follow-up data through
June 22, 2011. A total of 3,100 observations (727 partici-
pants) were used in this study. Each participating institute’s
institutional review board approved this study and written
informed consent was collected from each participant.
Blood pressure
The participants visited the study center in the morning.
The participants were asked not to smoke or drink for at
least 12 hours before a visit. Seating systolic blood pres-
sure (SBP) and fifth-phase diastolic blood pressure (DBP)
were measured to the nearest 2 mmHg. Blood pressures
were measured in the left arm and then in the right arm
with a standard mercury sphygmomanometer with a 14-
cm cuff. The mean measurements of the left and right
arms were used in this study. Pulse pressure was calcu-
lated as the difference between SBP and DBP.
Lead exposure
Bone lead measurement is used as an index of cumula-
tive lead exposure levels. Tibia (the mid-shaft of the left
tibia, cortical) and patella (the left patella, trabecular)
bone lead levels were measured using a K-x-ray fluores-
cence instrument (KXRF) (ABIOMED, Danvers, MA)
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uncertainty of tibia or patella bone lead levels, respect-
ively, (reflecting precision of the estimates) were ex-
cluded (n = 9). More details were published in a previous
study [27].
Genotyping
Multiplex polymerase chain reaction assays were de-
signed with Sequenom Spectro DESIGNER software
(Sequenon, Inc, San Diego, CA) by inputting sequences
containing the SNP site and 100 base pairs of flanking
sequence on either side of the SNP. In the VDR gene,
four SNP including Bsm1 (rs1544410), Taq1 (rs731236),
Apa1 (rs7975232), and Fok1 (rs10735810) were geno-
typed. More details on genotyping were provided in a
previous study [27].
Statistical analysis
When the data were investigated without assuming any
inheritance models for the SNPs, we observed that a
dominant inheritance model (in terms of minor fre-
quency allele) fits the data best (data not shown). For
dominant model, genotype was coded as 0 if a subject
had no minor frequency allele (ancestral type), or was
coded as 1 if a subject had one or two minor frequency
alleles (variant type). The study population was parti-
tioned based on the genotypes and compared with re-
gard to baseline characteristics. For each of the four
SNPs, the Hardy-Weinberg Equilibrium was checked for
an evidence of inbreeding, population stratification, and
problems in genotyping.
To account for the repeated measurements on pulse
pressure and covariates, linear mixed effects models with
random intercepts were implemented. We decomposed
age at examination into age-at-baseline and time-since-
baseline to capture the baseline age effect as well as the
longitudinal aging effect [28]. The main effects of bone
lead levels and VDR genotype, and their interaction term
were fitted adjusting for time-since-baseline and an
interaction term between time-since-baseline and bone
lead levels in addition to the following covariates: age at
baseline, race (White or not), body mass index (BMI),
smoking (pack-years), alcohol intake (two or more
drinks/day; Yes/No), calcium intake from food (calcium
(mg)/day), diabetes status (Yes/No), antihypertensive
medication status (Yes/No), family history of hyperten-
sion (Yes/No), education (less than high school, high
school, some college, or four year college or more), and
age at baseline by VDR genotype interaction. The inter-
action between time-since-baseline and bone lead would
capture different trajectories of pulse pressure over time
in relation to bone lead levels. A three-way interaction
among time-since-baseline, bone lead and VDR genetic
polymorphism was initially considered but not includedin our final model because it was almost null, suggesting
that the lead by VDR genotype interaction did not change
over time and that the lead by time-since-baseline inter-
action did not differ between the VDR genotypes. The
mixed model we used is described as follows:
Y ij e β0 þ β1⋅ lead þ β2⋅ SNP þ β3⋅ lead  SNP
þ β4⋅timeþ β5⋅ lead  timeþ covariatesþ ui þ ij;
where Yij is pulse pressure of subject i at time j, β0 is a
fixed intercept, β1-β5 are fixed coefficients representing
the estimated effects of each following term, ui is the
random intercept that reflects unexplained subject to
subject heterogeneity that induces correlation among
observations from the same subject, and ϵij is a random
error.
To interpret longitudinal associations of pulse pressure
with tibia levels, we computed the predicted values of
pulse pressure from the model with the continuous tibia
lead variable using the tibia bone lead values at the 25th
percentile and the 75th percentile of the distribution at
the baseline (time = 0) and after 10 years of follow-up
(time = 10) for the ancestral type and variant type, with
all covariates held constant at the mean (continuous var-
iables) or zero (categorical variables)
Results
All the four SNPs on the VDR gene, Bsm1, Taq1, Apa1,
and Fok1, are common SNPs with a minor allele frequency
range of 0.37 to 0.45 (Additional file 1: Table S1). All
SNPs were in Hardy-Weinberg equilibrium. The Bsm1
is in a strong linkage disequilibrium (r2 = 0.92) with
Taq1 in this study population but not with Apa1
(r2 = 0.54) or Fok1 (r2 = 0.001). Genotypes missing
rates were low (range: 1 - 6%). Among 727 participants,
442 participants (61%) had at least one copy of the Bsm1
minor frequency allele (bb or Bb, variant type) and 238
participants (33%) were homozygous for the major fre-
quency allele (BB, ancestral type). Forty seven subjects
(6%) had a missing Bsm1 genotype.
The mean age at baseline of the study population was
66 years (range: 48–93 years). The participants were
followed for up to 20 years. The median follow-up
period was longer for subjects who had at least one copy
of the Bsm1 minor frequency allele than for subjects
who did not have the minor frequency allele (12 years
vs. 9 years, Table 1). The number of follow-up examina-
tions ranged from 1 to 8 with a median of 4. More than
half of the participants were examined at least 5 times
over 10 years.
The subjects with a missing Bsm1 genotype were not
substantially different from the remaining subjects for
the baseline characteristics including age, race, BMI,
SBP, DBP, pulse pressure, and blood pressure control
Table 1 Characteristics of study population by the number of genetic variants at baseline
Characteristics Missing No. of minor frequency allele on Bsm1
All Bsm1 0 1 2
Number of subjects 727 47 (6%) 238 (33%) 316 (43%) 126 (17%)
Follow-up (years, mean ± SD) 10.6 ± 5.5 9.6 ± 6.2 9.9 ± 5.8 11.1 ± 5.2 11.3 ± 5.1
No. of follow-up exams (median (Q1-Q3)) 4 (3–6) 4 (2–6) 4 (2–6) 4.5 (3–6) 4.5 (3–6)
Continuous variables (mean ± SD)
Age at baseline (years) 66.4 ± 7.2 66.8 ± 8.9 66.7 ± 7.1 66.1 ± 7.1 66.6 ± 6.9
Height (m) 1.7 ± 0.1 1.7 ± 0.1 1.7 ± 0.1 1.7 ± 0.1 1.7 ± 0.1
Waist circumference (cm) 984.3 ± 94.1 97.6 ± 9.2 98.9 ± 9.4 985.1 ± 92.8 976.4 ± 98.3
Body Mass Index (kg/m2) 27.9 ± 3.7 27.4 ± 3.5 28.2 ± 3.9 27.9 ± 3.5 27.6 ± 3.7
High-density lipoprotein (HDL) cholesterol (mg/dL) 47.8 ± 12.4 47.4 ± 13.2 48.7 ± 12.3 47.5 ± 12.7 47.3 ± 11.5
Total cholesterol-to-HDL ratio 5.1 ± 1.5 5.3 ± 1.9 4.9 ± 1.3 5.1 ± 1.6 5.0 ± 1.3
Smoking (pack-years) 21.0 ± 25.1 21.5 ± 24.9 24.5 ± 28.2 19.6 ± 23.5 17.7 ± 22.2
Calcium intake (mg/day) 806 ± 404 916 ± 425 780 ± 388 817 ± 401 789 ± 427
Sodium intake (mg/day) 3855 ± 1841 4022 ± 1673 3770 ± 1700 3970 ± 2093 3658 ± 1407
Potassium intake (mg/day) 3363 ± 1386 3895 ± 1413 3212 ± 1232 3467 ± 1568 3191 ± 1067
Total calories intake (kcal/day) 1992 ± 637 2208 ± 770 1936 ± 651 2015 ± 615 1955 ± 599
Physical activity (kcal/week) 2002 ± 1788 1963 ± 1743 1879 ± 1755 2131 ± 1833 1921 ± 1752
Systolic blood pressure (mmHg) 136.0 ± 17.3 135.5 ± 18.2 137.6 ± 17.9 135.2 ± 17.8 135.3 ± 14.4
Diastolic blood pressure (mmHg) 81.7 ± 9.6 80.7 ± 10.6 83.2 ± 9.6 81.3 ± 9.3 80.3 ± 9.4
Pulse pressure (mmHg) 54.3 ± 14.7 54.8 ± 15.9 54.5 ± 14.5 53.8 ± 15.3 55.0 ± 12.8
Tibia lead level (μg/g) 21.2 ± 13.2 20.4 ± 14.5 22.2 ± 13.3 20.6 ± 13.2 21.2 ± 12.8
Patella lead level (μg/g) 30.5 ± 19.3 27.3 ± 15.9 31.9 ± 21.4 29.3 ± 17.8 32.0 ± 19.9
Blood lead level (μg/dL) 5.9 ± 3.9 6.0 ± 4.4 6.5 ± 4.1 5.7 ± 3.7 5.6 ± 3.7
Categorical variables (n(%))
Race (white or not) 703 (97%) 45 (96%) 227 (95%) 310 (96%) 121 (96%)
Alcohol (two or more drinks/day) 148 (20%) 7 (15%) 42 (18%) 76 (24%) 23 (18%)
Diabetes (diagnosed or taking medication) 94 (13%) 7 (15%) 28 (12%) 39 (12%) 20 (16%)
Antihypertensive medication 128 (18%) 8 (17%) 44 (18%) 54 (17%) 22 (17%)
Family history of hypertension 438 (60%) 21 (45%) 141 (59%) 201 (64%) 75 (60%)
Education: Less than high school 70 (10%) 1 (2%) 31 (13%) 19 (6%) 19 (15%)
Complete high school 248 (34%) 14 (30%) 87 (37%) 106 (34%) 41 (33%)
Some college 179 (25%) 15 (32%) 53 (22%) 81 (26%) 30 (24%)
College or more 204 (28%) 16 (34%) 62 (26%) 97 (31%) 29 (23%)
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levels, and the proportion of subjects with a family his-
tory of hypertension were slightly lower for those with
the missing genotype. In contrast, calcium, sodium, po-
tassium, and alcohol intake were slightly higher among
subjects with the missing Bsm1 genotype. The baseline
characteristics were similar between participants with
ancestral type and those with variant type. Participants
with ancestral type smoked more, had a higher DBP, and
had slightly lower prevalence of whites.
In longitudinal analyses, the two-way interaction be-
tween tibia bone lead levels and time-since-baseline wassignificant (estimate of the interaction term between
tibia bone lead and time-since-baseline in the Bsm1
model: −0.013, 95% CI = (−0.021, −0.005), p = 0.0008; in
the Taq1 model: −0.014, 95% CI = (−0.021, −0.006),
p = 0.0002), suggesting that the association between bone
lead levels and pulse pressure diminished over time. On
the other hand, the regression coefficient for the three-
way interaction term of VDR genotype, tibia bone lead
and time-since-baseline was close to zero (estimate of the
three-way interaction term in Bsm1: 0.005, 95% CI =
(−0.004, 0.014), p = 0.28; in Taq1: 0.004, 95% CI =
(−0.005, 0.013), p = 0.37). This suggests that the difference
Table 3 Adjusted changes in pulse pressure (mmHg) with
an IQR (20 μg/g) increase in patella lead levels
SNP N Ancestral vs. Variant Interaction term
β (95% CI)* β (95% CI)* P
Bsm1 811 Ancestral 0.0 (−1.6, 1.5) 1.9 (0.1, 3.8) 0.04
1619 Variant 1.9 (0.5, 3.2)
Taq1 822 Ancestral −0.1 (−1.6, 1.4) 2.0 (0.2, 3.8) 0.03
1753 Variant 2.0 (0.7, 3.3)
Apa1 789 Ancestral −0.1 (−1.8, 1.7) 1.7 (−0.3, 3.6) 0.09
1781 Variant 1.6 (0.4, 2.8)
Fok1 965 Ancestral 1.4 (−0.1, 2.9) 0.3 (−1.5, 2.2) 0.72
1545 Variant 1.7 (0.3, 3.1)
SNP: Single Nucleotide Polymorphism; N: Number of observations; IQR: Inter-quartile
range; P: p-value of the interaction term; Ancestral: major frequency allele
homozygotes; Variant: minor frequency allele homozygotes
and heterozygotes.
*To compute effect estimates from longitudinal models, the time term was
fixed at zero.
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by VDR genotype was constant during the follow-up.
Table 2 shows the estimated regression coefficients
and 95% confidence intervals for the association between
bone lead and pulse pressure by VDR genotype at base-
line (i.e., time is fixed at zero). With an interquartile
range (IQR) increase in tibia lead (15 μg/g), pulse pres-
sure was 2.5 mmHg (95% CI: 0.4-4.7) greater for the par-
ticipants with variant type on Bsm1 compared with the
participants with ancestral type (Table 2). With an IQR
increase in patella lead (20 μg/g), pulse pressure was
1.9 mmHg (95% CI: 0.1-3.8) greater for the participants
with at least one copy of the minor frequency allele in
Bsm1 compared with the participants without the minor
frequency allele (Table 3). Similar results were found for
Taq1. The interaction effect was relatively smaller for
Apa1 and Fok1.
In Figure 1, we shows the predicted values of pulse
pressure from the model with the continuous tibia lead
variable by Bsm1 genotype at baseline (time = 0) and
after ten years (time = 10). At baseline, as tibia bone lead
level increased from 13 μg/g (25th percentile) to 28 μg/g
(75th percentile), pulse pressure increased by 0.07 mmHg
(an IQR increase from 50.68 mmHg to 50.75 mmHg)
among subjects with Bsm1 ancestral type, while pulse
pressure increased by 2.6 mmHg (from 49.68 mmHg to
52.28 mmHg) among subjects with Bsm1 variant type.
After ten years, the marginal association (when the two
lines were combined ignoring the Bsm1 genotype) be-
tween tibia bone lead levels and pulse pressure became
weaker. After 10 years of follow-up, as tibia bone lead level
increased from 13 μg/g (25th percentile) to 28 μg/g (75th
percentile), pulse pressure decreased by 1.9 mmHg (from
54.09 mmHg to 52.19 mmHg) among Bsm1 ancestral typeTable 2 Adjusted changes in pulse pressure (mmHg) with
an IQR (15 μg/g) increase in tibia lead levels
SNP N Ancestral vs. Variant Interaction term
β (95% CI)* β (95% CI)* P
Bsm1 816 Ancestral 0.1 (−1.8, 1.9) 2.5 (0.4, 4.7) 0.02
1626 Variant 2.6 (1.2, 4.0)
Taq1 827 Ancestral 0.4 (−1.4, 2.2) 2.0 (−0.1, 4.1) 0.06
1760 Variant 2.4 (1.1, 3.8)
Apa1 795 Ancestral 1.5 (−0.4, 3.4) 0.3 (−1.9, 2.4) 0.81
1787 Variant 1.8 (0.4, 3.1)
Fok1 974 Ancestral 2.1 (0.5, 3.7) −0.02 (−2.0, 2.0) 0.99
1548 Variant 2.1 (0.6, 3.6)
SNP: Single Nucleotide Polymorphism; N: Number of observations; IQR:
Inter-quartile range; P: p-value of the interaction term; Ancestral: major
frequency allele homozygotes; Variant: minor frequency allele homozygotes
and heterozygotes.
*To compute effect estimates from longitudinal models, the time term was
fixed at zero.while pulse pressure increased by 0.63 mmHg (from
53.09 mmHg to 53.72 mmHg) among Bsm1 variant type
for the IQR change in tibia lead levels. In spite of the
changing association between bone lead levels and pulse
pressure over time, the effect modifications by VDR Bsm1
and Taq1 genotypes on the association between bone lead
levels and pulse pressure persists over time.
We also conducted cross-sectional analyses using base-
line data as a sensitivity analysis. The same covariates ex-
cept time-since-baseline and its interaction with lead
exposure levels were examined. Additional sensitivity ana-
lyses were done in order to investigate other possible con-
founders. Verifying analytical consistency, the interaction
effect of bone lead levels and the VDR genotype on pulse
pressure were examined by (i) adding the square of base-
line age, (ii) adding sodium (Na) and potassium (K) intake,
(iii) adding heart rate (sitting, beats/min), (iv) adding tri-
glyceride level, (v) adding high-density lipoprotein (HDL)
and total cholesterol-to-HDL ratio, (vi) adding total calo-
ries (kcal/day) and physical activity (expended (fast walk
adjusted), kcal/week), (vii) replacing BMI with height and
waist circumference, (viii) replacing two alcohol drinks per
day with grams per day of alcohol, (ix) replacing smoking
in pack-years with current smoker or not, (x) ignoring
calcium intake (obtained from a food frequency question-
naire), (xi) ignoring observations of subjects who are tak-
ing blood pressure control medication, and (xii) separating
the blood pressure control medication variable into two
variables: a calcium channel blocker and others.
We found slightly larger beta values in the cross-
sectional baseline analyses (Additional file 1: Table S2).
The magnitudes of the beta estimates slightly varied by
different covariate sets but the conclusions were consist-
ent (data not shown).
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Figure 1 The predicted values of pulse pressure from the linear mixed model with the continuous tibia lead variable using the tibia
bone lead values at the 25th percentile and the 75th percentile of the distribution at baseline (left) and after 10 years (right) for the
ancestral type (solid line) and variant (dashed line) of VDR Bsm1, with all other covariates held constant at the mean (continuous
variables: age at baseline (65 yrs), BMI (28 kg/m2), and calcium intake from food (800 mg/day)) or zero (categorical variables: race
(white), smoking (non-smoker), alcohol intake (less than two drinks/day), diabetes status (no), family history of hypertension (no), and
education (completed high school)).
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Using longitudinal observations, we found a stronger as-
sociation between cumulative bone lead levels and pulse
pressure in participants with at least one minor fre-
quency allele on Bsm1 or Taq1. The results were consist-
ent for tibia and patella bone lead levels. Our results
were robust to cardiovascular risk related confounding
factors in the sensitivity analyses. To our knowledge, this
is the first study showing the interplay of VDR genetic
polymorphisms and cumulative lead exposure levels on
a CVD subclinical measure in the longitudinal setting.
Pulse pressure is a marker of arterial stiffness, and ele-
vated pulse pressure is a risk factor of CVD. Pulse pres-
sure has been demonstrated as an independent predictor
of long-term cardiovascular mortality. A 10 mmHg in-
crease in pulse pressure has been associated with a 10 to
25% increase in risk for CVD related mortality among
older adults including coronary heart disease, congestive
heart failure, and cerebrovascular disease [29-31]. In the
present study, we found that individuals with at least
one VDR Bsm1 variant had a 2.5 mmHg greater pulse
pressure in relation to every 15 μg/g increase in cumula-
tive (tibia) lead exposure. We interpret this suggesting
that individuals with VDR Bsm1 at least one variant may
have 2.5% to 6% greater risks for CVD mortality for
every 15 μg/g increase in cumulative lead exposure.
The two genetic polymorphisms, that we found to
interact with the cumulative lead exposure, are common
SNPs with minor allele frequency over 0.4 in American
Caucasians (Additional file 1: Table S1). Over 65% of
European descendants have at least one copy of these
genetic polymorphisms, based on HapMap Phase 3
European ancestry samples [32], suggesting that over
65% of European descendants may be susceptible tocumulative lead exposure related elevation in pulse pres-
sure. Thus, the lead by VDR interaction found in this
study may explain some portion of CVD events and
mortality in the elderly.
Underlying biological mechanisms, by which the VDR
genetic polymorphisms may modify the effect of lead on
cardiovascular disease, are not well understood. Individ-
uals with VDR genetic variants may have higher body
burdens of lead, suggesting that the VDR gene may
modify the toxicokinetics of lead [12,24,33,34]. In a
study of Korean lead workers, blood lead levels and tibia
bone lead levels were significantly higher in participants
with the VDR Bsm1 minor frequency allele [35]. Another
study of former organolead manufacturing workers in the
eastern United States suggested that the VDR Bsm1 vari-
ant influences lead uptake and subsequent release of lead
from bone [16]. The interaction between the VDR and
lead can be explained by calcium metabolism. The VDR
plays a crucial role in calcium absorption and metabolism,
which is shared by lead from its divalent cation character-
istic. Calcium deficiency was demonstrated to increase
lead absorption in the gastrointestinal tract in chicks
[36,37]. Ingestion of lead inhibits the effect of vitamin D
and its metabolites on intestinal calcium transport in
rats [38]. In addition, associations between high bone
and blood lead levels and hypertension were also found
among subjects with low dietary calcium intake in the
NAS [4].
An interaction between the VDR gene and lead was
also found to be involved in diverse disease develop-
ment processes. In a study of the US general population,
adults aged 60 years and older with the VDR rs2239185–
rs731236 (Taq1) CC haplotype showed a negative asso-
ciation between blood lead and serum homocysteine, a
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those with the VDR rs2239185–rs731236 CT or TT
showed a positive association [23]. In the same study,
adults aged 20 to 59 years of age who had VDR
rs2239185–rs731236 CC or TT haplotypes, showed sig-
nificant decline in cognitive function with increased
blood lead concentration while those CT haplotype did
not show significant decline. In a study of lead and cre-
atinine among Korean lead workers, the VDR Bsm1
genotype was also found to modify the association be-
tween tibia bone lead and renal function as assessed by
serum creatinine level and creatinine clearance [24].
The lead workers with at least one minor frequency
allele on VDR Bsm1 showed worse renal function with
higher lead exposure levels. Another study of the
Korean lead workers demonstrated an effect modifica-
tion of the VDR Bsm1 genotype on the association be-
tween lead exposure and blood pressure [39]. Among
lead workers with the VDR Bsm1 variant, SBP were 2.7-
3.7 mmHg higher and prevalence of hypertension was
higher (OR =2.1). Thus, our results and those of others
support the concept of interaction between the VDR ge-
notypes and lead.
We observed a significant negative interaction between
time-since-baseline and tibia bone lead levels in the lon-
gitudinal analyses. The negative interaction can be inter-
preted in two different ways: the association between
tibia bone lead and pulse pressure may decrease during
the follow-up or the association between time-since-
baseline and pulse pressure may decrease with higher
lead exposure levels. A possible explanation for the de-
creasing effect of cumulative lead levels on pulse pressure
during the follow-up is that people who had developed
health related problems or diseases were more likely to
drop out during follow-up [40]. Hence, the participants
who stayed longer in the study may be healthier than
those who dropped out. Another possible explanation is
that other atherosclerotic risk factors became more pro-
nounced as the study participants get older. As a result,
the association between lead exposure and pulse pressure
may seem attenuated over time. Alternatively, we have
already reported that bone lead concentrations are falling
in these participants, and more quickly for patella lead
[41]. This suggests that the weaker associations between
the baseline bone lead levels and the follow-up pulse pres-
sures could reflect the lower exposure at later follow-up
visits. In spite of the changing association between bone
lead levels and pulse pressure over time, our main interest,
the effect modifications by VDR Bsm1 and Taq1 genotypes
on the association between bone lead levels and pulse
pressure were consistent over time (Figure 1).
We see consistent results with regard to Bsm1 and
Taq1. These SNPs are closely located to each other in
the VDR gene (distance between Bsm1 and Taq1 = 1 kilobase pairs, size of the VDR gene = 63 kilo base pairs).
The two SNPs are in high linkage disequilibrium
(r2 = 0.92). Among participants with at least one minor
frequency allele on Bsm1, 98% had at least one minor
frequency allele on Taq1. This explains why Bsm1 and
Taq1 show similar effect modification signals. And this
consistent results support that our finding is less likely
to be a false positive from genotyping errors on Bsm1 or
Taq1. In the VDR gene, Bsm1 is located in intron8, and
Taq1 is located in exon9. Genetic polymorphisms in in-
tron regions, where splice enhances or silencers bind,
can have an effect on alternative splicing [42]. More than
60% of the alternatively spliced variants in humans re-
sults in changes in the protein structure which may re-
sult in conformational changes [43]. However, whether
these SNPs, Bsm1 and Taq1, are the functional poly-
morphism with an effect on the structure of vitamin D
receptor or on the affinity of the receptor, or whether
they are in high linkage disequilibrium with some other
functional SNPs is unclear. It should be further investi-
gated in animal studies or in vitro studies.
The strengths of the current study include reliable
bone lead measurements and extensive follow-ups up to
20 years (median follow-up of 9 years and median num-
ber of follow-up examinations of 4). The repeated mea-
surements in pulse pressure and covariates increase
statistical power to detect the gene by environment in-
teractions. However, the NAS is an older cohort of pre-
dominantly white male participants. Hence, the findings
may not be generalizable to women, younger individuals,
and other ethnicities.
Conclusion
Lead toxicity is found in almost every systems in the
body. Over 90% of the total body lead burden in adults
is accumulated in the bone and only about 1% is found
in the blood [44]. Even though blood lead levels have
been gradually reduced since the phase-out of leaded
gasoline in the 1970s, cumulative lead levels are still sub-
stantial in the elderly and associated with diverse diseases
including cognitive function decline and hypertension
[2,45]. Our finding suggests that subjects with the minor
frequency alleles of VDR Bsm1 or Taq1 may be more sus-
ceptible to cumulative lead exposure-related elevated
pulse pressure. If the VDR gene is involved in the associ-
ation between lead and pulse pressure, calcium metabol-
ism may play an important role in lead toxicity in CVD.
The observed interaction between cumulative lead levels
and the VDR Bsm1 or Taq1 persists over time during the
follow-up. This implies that the elderly experience adverse
effects from their early lead exposure, even though current
ambient lead levels are low. Our findings suggest the im-
portance of restricting early exposure to lead to avoid its
persistent adverse health effects in the subjects’ later life.
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